US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.31

+0.57003.21%

Post-market: 18.310.00000.00%19:30 EDT

Volume:26.07K

Turnover:476.69K

Market Cap:108.03M

PE:- -

High:18.36

Open:18.30

Low:18.11

Close:17.74

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:0.47

T/O Rate:0.44%

Dividend:0.71

Dividend Rate:3.90%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

CMB International Lifts WUXI BIO Price Target to HK$60, Maintains "Buy" Rating

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live

Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy

MT Newswires Live

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Biocytogen Pharmaceuticals H1 Revenue up 51.6%

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.

Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating

Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/KURE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.31,"timestamp":1789416000000,"preClose":17.74,"halted":0,"volume":26065,"hourTrading":{"tag":"盘后","latestPrice":18.31,"preClose":18.31,"latestTime":"19:30 EDT","volume":12,"amount":219.72,"timestamp":1789428601637,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.032130777903043986,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"Closed","change":0.57,"latestTime":"09-14 16:00:00 EDT","open":18.3,"high":18.3599,"low":18.1101,"amount":476691.00362,"amplitude":0.014081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":17.74,"sharesOutstanding":4750002,"nav":17.75,"aum":104708978.23,"dividendRate":0.039039,"bidAskSpread":0.008219,"postHourTrading":{"tag":"盘后","latestPrice":18.31,"preClose":18.31,"latestTime":"19:30 EDT","volume":12,"amount":219.72,"timestamp":1789428601637,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.466743,"impliedVol":0.2574,"impliedVolPercentile":0.5139},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.466743,"shares":5900168,"dividePrice":0.7148,"high":18.3599,"amplitude":0.014081,"preClose":17.74,"low":18.1101,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":18.31,"eps":0,"divideRate":0.039039,"volume":26065,"delay":0,"ttmEps":0,"open":18.3,"prevYearClose":17.04,"prevWeekClose":17.74,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":18.9,"twentyDayClose":18.43,"sixtyDayClose":14.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662058969","title":"Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662058969?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:45","pubTimestamp":1787885100,"startTime":"0","endTime":"0","summary":"HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","LU1854104046.USD","LU2360107325.USD","LU1983260115.SGD","LU2298322129.HKD","LU2399975544.HKD","BK4141","LU0348784397.USD","LU1861220033.SGD","LU2357305700.SGD","COAL","LU2488822045.USD","BK4135","LU0417516571.SGD","LU0348723411.USD","IE00B543WZ88.USD","LU0634319403.HKD","LU0348827113.USD","BK4211","LU0348825331.USD","BK4585","LU1794554557.SGD","LU1861214812.USD","BK1161","LU2778985437.USD","IE00BPRC5H50.USD","LU1720051017.SGD","BK4006","ONG","ONX","PFS","LU0561508036.HKD","ON","LU2476274720.SGD","09926","LU0417516902.SGD","IE00BFMHRM44.USD","CNS","LU0348766576.USD","HCC","BK4588","LU1854103824.USD","LU0348735423.USD","KURE","BK4195","LU1861215975.USD","LU1548497426.USD","LU1720051108.HKD","IE00B5MMRT66.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145217194","title":"CMB International Lifts WUXI BIO Price Target to HK$60, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1145217194","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145217194?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:44","pubTimestamp":1787885052,"startTime":"0","endTime":"0","summary":"CMB International has released a research report highlighting WUXI BIO (02269)'s strong first-half performance, which prompted an upward revision of its full-year revenue growth guidance to 15%-18%....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","KURE","LU0307460666.USD","LU0856984785.SGD","BK1521","LU0456846285.SGD","LU3063872942.SGD","LU0320764599.SGD","LU0326950275.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","LU0572944931.SGD","LU0516423174.USD","LU0327786744.USD","LU0039217434.USD","LU0516422952.EUR","PRTO","LU0128526141.USD","LU0588546209.SGD","SG9999002562.SGD","LU0456827905.SGD","LU1242518857.USD","LU0051755006.USD","LU0140636845.USD","LU0052750758.USD","LU1880383366.USD","LU0516423091.SGD","LU0819121731.USD","LU0516422440.USD","LU0823426480.USD","LU1688375341.USD","BK1589","BK1576","LU0029874061.USD","LU0348735423.USD","LU1242518931.SGD","LU0823426308.USD","BK1141","LU0348825331.USD","LU0181495838.USD","LU0708995583.HKD","LU0417516738.SGD","BK1610","LU0979878070.USD","02269","EWH","LU0516422366.SGD","LU1720050803.USD","LU0359201612.USD","LU2039709279.SGD","LU0417516902.SGD","SG9999002463.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203452","title":"Akeso's Losses Narrow in H1 as Revenue Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203452","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203452?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:06","pubTimestamp":1787875618,"startTime":"0","endTime":"0","summary":"Akeso  reported an attributable loss of 424.2 million yuan for the first half, narrowing from a loss of 570.1 million a year earlier.Loss per share stood at 0.46 yuan, compared with 0.64 yuan in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.The biotech company's revenue increased 28% year over year to 1.81 billion yuan for the six months ended June 30 from 1.41 billion yuan.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348735423.USD","09926","FCA","LU0417516738.SGD","KURE","LU0348827113.USD","IE00B543WZ88.USD","LU0348784397.USD","BK1161","IE00B5MMRT66.SGD","LU0348783233.USD","LU2399975544.HKD","LU0540923850.HKD","LU2476274720.SGD","LU0417516571.SGD","LU0348766576.USD","IE00BPRC5H50.USD","LU0348825331.USD","LU0561508036.HKD","LU2476274308.USD","LU1794554557.SGD","LU2488822045.USD","LU0634319403.HKD","LU1720050803.USD","LU0417516902.SGD","LU2778985437.USD","LU0348767384.USD","BK1574","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662378920","title":"Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662378920","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662378920?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:45","pubTimestamp":1787870742,"startTime":"0","endTime":"0","summary":"It's been a good week for Innovent Biologics, Inc. ( HKG:1801 ) shareholders, because the company has just released its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/earnings-beat-innovent-biologics-inc-just-beat-analyst-forec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/earnings-beat-innovent-biologics-inc-just-beat-analyst-forec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2097828631.EUR","KURE","VGFPF","LU0455707207.USD","LU2488822045.USD","PMDE","GXDW","LU2097828474.EUR","VOTE","LU2097828805.USD","01801","LU2097828714.EUR","HK0000165453.HKD","DECU","LU0244354667.USD","RGLO","LU2097828557.USD","LU1188198961.HKD","LU0326950275.SGD","LU1969619763.USD","LU0502904849.HKD","LU2328871848.SGD","BK1583","LU0463099449.HKD","BK1161","FEBU","LU2242644610.SGD","BK1589","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086799","title":"Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086799","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662086799?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:51","pubTimestamp":1787842274,"startTime":"0","endTime":"0","summary":"Innovent Biologics files HKEX next-day disclosure return, issues 182,021 new sharesInnovent filed a next-day disclosure return on Aug. 27, 2026 for share issuances from option exercises.Issued 182,021","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL82CCyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1583","BK1147","KURE","LU2097828805.USD","LU2488822045.USD","LU2097828557.USD","LU2097828714.EUR","BK1589","LU2097828631.EUR","01801","HK0000165453.HKD","LU0463099449.HKD","LU1188198961.HKD","LU1969619763.USD","LU2097828474.EUR","BK1161","01911","LU0502904849.HKD","LU0244354667.USD","LU0326950275.SGD","LU2242644610.SGD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790083","title":"Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:00","pubTimestamp":1787839249,"startTime":"0","endTime":"0","summary":"Akeso FY26 H1 net loss narrows 23.98% to RMB 447.2 million; revenue rises 27.92% to RMB 1.81 billionAkeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL34jFkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","09926","LU2778985437.USD","LU0417516571.SGD","LU1961090484.USD","LU2399975544.HKD","LU1794554557.SGD","LU0348767384.USD","LU0417516902.SGD","LU0561508036.HKD","BK1574","LU2476274308.USD","LU1720050803.USD","LU0540923850.HKD","LU0348784397.USD","LU0348735423.USD","LU0348766576.USD","LU0348825331.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","KURE","LU2488822045.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662980702","title":"Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662980702","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662980702?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:05","pubTimestamp":1787832345,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) has an average rating of buy and mean price target of HK$127.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","LU2097828557.USD","LU2488822045.USD","LU0326950275.SGD","LU0502904849.HKD","LU2328871848.SGD","01801","BK1589","LU1969619763.USD","LU1188198961.HKD","LU2242644610.SGD","LU0455707207.USD","LU0244354667.USD","BK1161","LU0463099449.HKD","KURE","LU2097828714.EUR","LU2097828805.USD","LU2097828631.EUR","HK0000165453.HKD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662046377","title":"China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662046377","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662046377?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:40","pubTimestamp":1787830849,"startTime":"0","endTime":"0","summary":"China's CStone Pharmaceuticals H1 revenue soars on drug salesOverviewChina biopharma firm's half-year revenue rose 315% yr/yr to RMB205.1 mlnRevenue growth driven by higher pharmaceutical sales, espec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","03692","LU2097828805.USD","LU1188198961.HKD","HK0000165453.HKD","LU0455707207.USD","BK1583","KURE","LU2097828631.EUR","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","02616","BK1589","BK1161","01801","LU0244354667.USD","LU2097828474.EUR","LU2328871848.SGD","BK0216","LU0326950275.SGD","BK1191","LU2097828714.EUR","688796","LU0502904849.HKD","LU1969619763.USD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662457709","title":"CSPC Pharma Gets Trial Nod for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662457709","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662457709?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:05","pubTimestamp":1787828740,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0008368742.USD","LU0072913022.USD","LU1813983027.USD","IE00BZ08YT58.USD","LU1328277881.USD","LU1951186391.HKD","LU0315179316.USD","SG9999004220.SGD","LU0326950275.SGD","LU0501845795.SGD","LU2039709279.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU1993786604.SGD","LU1226287792.SGD","HK0000165453.HKD","LU0880133367.SGD","LU1152091168.USD","LU1226287875.USD","KURE","01093","IE00B031HY20.USD","LU1807302812.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU1226288253.USD","IE00B543WZ88.USD","LU0314109678.HKD","IE0008369823.USD","BK1191","LU0140636845.USD","BK1515","BK1521","IE00B5MMRT66.SGD","LU1226287529.USD","LU1008478684.HKD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191071495","title":"CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1191071495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191071495?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826628,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its developed SYH2092 injection has received approval from China's National Medical Products Administration to proceed with clinical trials within the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","PSYK","MDTX","LU0326950275.SGD","LU1328277881.USD","LU1813983027.USD","LU1226288170.HKD","LU0072913022.USD","IE0008368742.USD","KURE","LU2039709279.SGD","IE00B031HY20.USD","HK0000165453.HKD","LU0140636845.USD","IBBQ","LU1226287529.USD","LU0880133367.SGD","LU0315179316.USD","01093","IE00B543WZ88.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1960683339.HKD","LU1226287875.USD","LU0067412154.USD","IE00BZ08YR35.GBP","IBBJ","IE00BZ08YT58.USD","LU1226288253.USD","BK1191","LU0314109678.HKD","LU1152091754.HKD","BK1521","LU0501845795.SGD","BK1515","LU1807302812.USD","LU1152091168.USD","LU1226287792.SGD","LU1993786604.SGD","SG9999004220.SGD","IE00BZ08YS42.EUR","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703286","title":"CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703286?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825977,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2092 amylin agonist injectionCSPC won China NMPA clearance to start clinical trials of SYH2092, an amylin receptor agonist injection for obesity.Program ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL60gfrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","IE00BZ08YS42.EUR","LU1226287875.USD","LU0314109678.HKD","01093","IE0008368742.USD","BK1191","LU1226287792.SGD","LU1807302812.USD","LU1951186391.HKD","SG9999004220.SGD","IE0008369823.USD","KURE","LU1813983027.USD","IE00B031HY20.USD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1993786604.SGD","LU1152091754.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0140636845.USD","LU1226287529.USD","BK1521","LU1960683339.HKD","LU0315179316.USD","LU0067412154.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226288253.USD","LU1152091168.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1328277881.USD","BK1515","LU1008478684.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703472","title":"CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703472?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0326950275.SGD","IE0008369823.USD","HK0000165453.HKD","01093","LU1813983027.USD","KURE","LU0072913022.USD","LU0501845795.SGD","LU1328277881.USD","LU0140636845.USD","LU0880133367.SGD","LU1951186391.HKD","IE00BZ08YT58.USD","LU1226287875.USD","LU1226287792.SGD","IE00B543WZ88.USD","LU1152091168.USD","LU1807302812.USD","IE00BZ08YR35.GBP","LU0067412154.USD","LU1226288170.HKD","LU1226287529.USD","LU1152091754.HKD","LU1993786604.SGD","LU0315179316.USD","LU1960683339.HKD","LU1226288253.USD","IE00B031HY20.USD","BK1191","LU1008478684.HKD","SG9999004220.SGD","BK1515","BK1521","IE0008368742.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU2039709279.SGD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471703","title":"CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","LU0140636845.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","SG9999004220.SGD","IE00B543WZ88.USD","BK1515","LU0314109678.HKD","LU2039709279.SGD","LU0072913022.USD","BK1191","LU1813983027.USD","IE00BZ08YT58.USD","LU1993786604.SGD","LU0067412154.USD","LU1152091168.USD","LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU1328277881.USD","IE00B031HY20.USD","LU1807302812.USD","LU0880133367.SGD","LU1226287875.USD","LU1951186391.HKD","IE0008369823.USD","HK0000165453.HKD","LU1008478684.HKD","LU1226288253.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1226287792.SGD","KURE","LU1960683339.HKD","LU1226288170.HKD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0395794307.EUR","KURE","IYH","LU0708994859.HKD","TRUH","LU2362541513.USD","LU2097828714.EUR","MADE","BBH","LU0943347566.SGD","LU1037948897.HKD","LU2237443978.SGD","LU1244550577.SGD","IE000SO60NU8.SGD","REGN","LU0859254822.USD","FHLC","MEDX","LU1934455863.HKD","IE00BVYPNV92.GBP","ABBV","01801","LU1934455277.USD","TBXU","GLAM","FTXH","JDOC","LU0310799852.SGD","LU1188198961.HKD","VHT","BK1574","RXL","IE0004445239.USD","IBBQ","PJP","CMI","IXJ","XLV","IE00BN8TJ469.HKD","AGNG","02126","IBB","LU0463099449.HKD","LU0949170772.SGD","PPH","LU0432979614.USD","LU2237443382.USD","688331","03692","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774568","title":"Biocytogen Pharmaceuticals H1 Revenue up 51.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774568","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774568?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:41","pubTimestamp":1787820113,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals H1 revenue up 51.6%OverviewChina biotech firm's H1 revenue rose 51.6% yr/yr to RMB941.4 mlnNet profit attributable to shareholders up 402.3% to RMB241.1 mlnCompany cites str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764599.SGD","LU0307460666.USD","02315","LU0516422366.SGD","LU0455707207.USD","LU2328871848.SGD","LU1794554557.SGD","LU0823426480.USD","LU2097828631.EUR","BK1583","LU0588546209.SGD","LU0359202008.SGD","LU0140636845.USD","LU0051755006.USD","LU0039217434.USD","01801","LU1242518857.USD","LU0463099449.HKD","LU0244354667.USD","LU1880383366.USD","LU0516422440.USD","LU0417516902.SGD","LU0516423091.SGD","LU1720050803.USD","LU0456846285.SGD","BK1161","KURE","LU0572944931.SGD","LU0348735423.USD","02269","LU0819121731.USD","LU0979878070.USD","LU3063872942.SGD","LU0856984785.SGD","BK1576","LU0823426308.USD","LU2488822045.USD","03692","LU0417516738.SGD","BK1191","688796","BK1521","LU0516423174.USD","LU2097828474.EUR","LU0502904849.HKD","LU2097828805.USD","LU2039709279.SGD","IE00B0JY6N72.USD","LU0128526141.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977171","title":"CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977171","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977171?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:20","pubTimestamp":1787815224,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.\nThe recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BZ08YR35.GBP","LU1226287529.USD","LU1328277881.USD","LU0314109678.HKD","LU2039709279.SGD","LU0140636845.USD","LU1226288253.USD","BK1191","GXDW","01093","IE00B543WZ88.USD","KURE","IE0008369823.USD","LU1152091168.USD","IE00B031HY20.USD","LU1813983027.USD","LU1152091754.HKD","DCF","LU1951186391.HKD","PMDE","LU0501845795.SGD","VGFPF","RGLO","BK1521","HK0000165453.HKD","LU1226287792.SGD","LU0880133367.SGD","LU0067412154.USD","LU0315179316.USD","SG9999004220.SGD","BK1515","VOTE","IE0008368742.USD","LU1008478684.HKD","LU1807302812.USD","LU1993786604.SGD","LU0072913022.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1226288170.HKD","IE00BZ08YT58.USD","JOYT","DECU","LU0326950275.SGD","FEBU","IE00B5MMRT66.SGD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133409443","title":"Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1133409443","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133409443?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:20","pubTimestamp":1787811619,"startTime":"0","endTime":"0","summary":"Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2097828557.USD","LU0502904849.HKD","HK0000165453.HKD","LU2097828474.EUR","LU0326950275.SGD","BK1589","LU2328871848.SGD","01801","BK1161","LU1969619763.USD","LU2488822045.USD","LU2097828714.EUR","KURE","LU0455707207.USD","LU2097828805.USD","LU0463099449.HKD","LU2242644610.SGD","EWH","LU1188198961.HKD","LU0244354667.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773368","title":"Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773368","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773368?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:01","pubTimestamp":1787810460,"startTime":"0","endTime":"0","summary":"0601 GMT - Innovent Biologics' outlicensing drug deals with multinational corporations could remain a key share-price driver, say DBS Group Research analysts in commentary. The Chinese biopharmaceutical company's previous deal with Pfizer in May boosted its stock by around 33% over two months. Innovent likely has around three early stage treatment products that could yield around $955 million in upfront payments, the analysts estimate. The company's balance sheet also remains strong, with net cash of around 16.2 billion yuan as of June, they add. DBS Group Research maintains its buy rating and 144.00 Hong Kong dollar target price. Shares drop 2.55% to HK$107.00.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU2097828714.EUR","HK0000165453.HKD","LU2488822045.USD","LU2097828631.EUR","LU2242644610.SGD","LU0244354667.USD","LU0502904849.HKD","LU2097828557.USD","KURE","LU1188198961.HKD","LU2328871848.SGD","BK1583","LU2097828474.EUR","LU2097828805.USD","01801","LU1969619763.USD","BK1161","LU0463099449.HKD","BK1589","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727075","title":"China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662727075?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:42","pubTimestamp":1787805765,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's drug regulator accepts Novo Nordisk's application for oral WegovySHANGHAI, Aug 27 (Reuters)-Novo NordiskNOVOb.COsaid on Thursday that China's drug regulator had accepted its applicati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O09E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","BK1161","LU0868494617.USD","SG9999001176.USD","LU0985481810.HKD","OZEM","PFE","IE00BLSP4452.SGD","SG9999011175.SGD","LU2242644610.SGD","SG9999002232.USD","LU0455707207.USD","LU0170899867.USD","LU0225771236.USD","IE0002270589.USD","BK4568","LU2097828474.EUR","BK4581","SG9999001176.SGD","LU0463099449.HKD","LU1894683348.USD","BK4007","IE00BBT3K403.USD","BK4533","01801","LU1894683264.USD","LU1057294990.SGD","LU0058720904.USD","LU2328871848.SGD","SGXZ57979304.SGD","LU0502904849.HKD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","HK0000165453.HKD","BK1583","BK1197","LU2097828631.EUR","LU0321505868.SGD","00673","LU0456855351.SGD","KURE","BK1589","IE00B19Z3581.USD","LU0122379950.USD","LU2097828557.USD","BK4588","IE00BLSP4239.USD","BK4599","LU0321505439.SGD","LU2596442595.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185413400","title":"Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1185413400","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185413400?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:01","pubTimestamp":1787799711,"startTime":"0","endTime":"0","summary":"Akeso (09926) climbed more than 6% during Wednesday's trading session before paring gains, last up 2.34% at HK$96.40 with turnover reaching HK$686 million.On August 26, Akeso announced that its phase...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU0348783233.USD","LU0348825331.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK0188","002736","LU0348735423.USD","LU1720050803.USD","LU2778985437.USD","LU0348827113.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348767384.USD","LU2488822045.USD","BK0028","BK0183","IE00BPRC5H50.USD","LU1794554557.SGD","LU0417516571.SGD","BK1161","LU0348766576.USD","LU0540923850.HKD","LU2476274720.SGD","09926","KURE","BK0276","LU1961090484.USD","BK1574","LU0561508036.HKD","LU2476274308.USD","LU0348784397.USD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}